Italy’s Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1 Billion
Italy’s Angelini Pharma S.p.A. entered a merger agreement on May 7, 2026, to acquire Catalyst Pharmaceuticals, Inc. (CPRX) in an all-cash deal valued at $4.1 billion. Deal…
Written byAsif SuriaSource: InsideArbitrage
Italy’s Angelini Pharma S.p.A. entered a merger agreement on May 7, 2026, to acquire Catalyst Pharmaceuticals, Inc. (CPRX) in an all-cash deal valued at $4.1 billion. Deal Structure: Angelini Pharma has agreed to acquire all outstanding shares of Catalyst for $31.5 per share in cash, representing a premium of 3.21% from the stock’s last close.